As 2025 ends, delve into some biotech feel-good stories where the right treatment meets the right patient, almost feeling ...

A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

BIO-Europe Startup Spotlight returns to Lisbon in March 2026, showcasing Europe’s top early-stage biotech pitches to industry ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

The need for change in Novo Nordisk’s operations became irrefutably clear in July, when the company named its new CEO, Maziar Mike Doustdar, and simultaneously issued a profit warning for its ...

In June, AstraZeneca once again turned to the Chinese company CSPC Pharmaceuticals, with whom it initially entered into an exclusive license agreement in October 2024 for an early-stage cardiovascular ...

A company that hardly needs an introduction is Eli Lilly, but what has it been up to lately, and what’s its pipeline strategy? Over the past year, Lilly has mixed headline-grabbing science with ...

Once a booming field, bustling with innovation and money driving that innovation, the cell and gene therapy sector is now struggling to fuel therapeutic growth to bring medicines to patients. It doesn ...

The news that the organization led a $35 million funding round for London-based Portal Biotech came about two weeks ago. Portal Biotech’s focus is on the field of proteomics, which is the study of ...